期刊
ACTA TROPICA
卷 221, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.actatropica.2021.105990
关键词
Chagas disease; Trypanosoma cruzi; Chronic infection; Chemotherapy response; Antigens; PFR2; KMP11; HSP70; 3973; F29; InfYnity multiplexed ELISA
资金
- Departament d'Universitats i Recerca de la Generalitat de Catalunya, Spain (AGAUR) [2017SGR00924]
- Instituto de Salud Carlos III project [PI18/01054]
- RICET Network for Cooperative Research in Tropical Diseases [RD12/0018/0010]
- FEDER
- Spanish Ministry of Science Innovation and Universities through the Centro de Excelencia Severo Ochoa 2019-2023 Program [CEX2018-000806S]
- Generalitat de Catalunya through the CERCA Program
- Programa Estatal I + D + i (MINECO) [SAF2016-81003R, SAF2016-80998R]
- ISCIII RICET [RD16/0027/0005]
- Ministry of Health, Government of Catalunya [PERIS 2016-2010 SLT008/18/00132]
- Conselho Nacional de Pesquisa e Desenvolvimento Tecnologico [CNPq/313011/2018-4]
- Fundacao Oswaldo Cruz/MS [25380.001603/2017-89]
- Drugs for Neglected Diseases initiative
- UK Aid, UK
- Directorate-General for International Cooperation (DGIS) , The Netherlands
- Swiss Agency for Development and Cooperation (SDC) , Switzerland
- Medecins Sans Frontieres (MSF), International
- Fundacion Mundo Sano
Chagas disease, caused by Trypanosoma cruzi, affects over 6 million people worldwide, with 30% developing life-threatening disorders in the chronic phase. Lack of biomarkers for timely assessment of therapeutic response hinders treatment evaluation and discourages use of available anti-parasitic drugs. Further studies are needed to determine the potential role of specific antigens as treatment response biomarkers.
Chagas disease, caused by the protozoan Trypanosoma cruzi, affects more than 6 million people worldwide. Following a mostly asymptomatic acute phase, the disease progresses to a long-lasting chronic phase throughout which life-threatening disorders to the heart and/or gastrointestinal tract will manifest in about 30% of those chronically infected. During the chronic phase, the parasitemia is low and intermittent, while a high level of antiT. cruzi antibodies persist for years. These two features hamper post-chemotherapeutic follow-up of patients with the tools available. The lack of biomarkers for timely assessment of therapeutic response discourages a greater use of the two available anti-parasitic drugs, and complicates the evaluation of new drugs in clinical trials. Herein, we investigated in a blinded case-control study the serological reactivity over time of a group of parasitederived antigens to potentially address follow up of T. cruzi chronically infected subjects after treatment. We tested PFR2, KMP11, HSP70, 3973, F29 and the InfYnity multiplexed antigenic array, by means of serological assays on a multi-national retrospective collection of samples. Some of the antigens exhibited promising results, underscoring the need for further studies to determine their potential role as treatment response biomarkers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据